Cellular Biomedicine Group (NASDAQ:CBMG) Upgraded by BidaskClub to “Hold”

Cellular Biomedicine Group (NASDAQ:CBMG) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Saturday, June 29th, BidAskClub reports.

Separately, Cantor Fitzgerald set a $33.00 price target on Aldeyra Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $27.50.

CBMG traded down $0.53 during trading on Friday, reaching $14.38. 22,465 shares of the company were exchanged, compared to its average volume of 39,764. The firm has a market capitalization of $276.53 million, a PE ratio of -7.05 and a beta of 2.56. The business’s 50 day moving average price is $14.87. Cellular Biomedicine Group has a 52 week low of $12.04 and a 52 week high of $25.00.

Cellular Biomedicine Group (NASDAQ:CBMG) last issued its quarterly earnings data on Tuesday, April 30th. The biotechnology company reported ($0.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.57) by $0.06. The firm had revenue of $0.05 million during the quarter. Cellular Biomedicine Group had a negative return on equity of 42.41% and a negative net margin of 17,921.62%. As a group, analysts forecast that Cellular Biomedicine Group will post -2.08 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in CBMG. Nikko Asset Management Americas Inc. acquired a new stake in shares of Cellular Biomedicine Group in the first quarter valued at $6,721,000. Sumitomo Mitsui Trust Holdings Inc. purchased a new stake in shares of Cellular Biomedicine Group during the first quarter valued at $6,622,000. ARK Investment Management LLC purchased a new stake in shares of Cellular Biomedicine Group during the first quarter valued at $4,944,000. BlackRock Inc. lifted its holdings in shares of Cellular Biomedicine Group by 3.8% during the fourth quarter. BlackRock Inc. now owns 657,998 shares of the biotechnology company’s stock valued at $11,620,000 after purchasing an additional 23,992 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in shares of Cellular Biomedicine Group by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 126,067 shares of the biotechnology company’s stock valued at $2,226,000 after purchasing an additional 14,621 shares during the last quarter. Institutional investors and hedge funds own 17.87% of the company’s stock.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer and orthopedic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for treating a range of cancer indications comprising technologies in chimeric antigen receptor modified T cells (CAR-T), a genetically modified T-cell receptors (TCRs), and next generation neoantigen-reactive tumor infiltrating lymphocytes; and human adipose-derived mesenchymal progenitor cells for the treatment of joint diseases.

Featured Article: The role of implied volatility with call option volume

Receive News & Ratings for Cellular Biomedicine Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group and related companies with MarketBeat.com's FREE daily email newsletter.